Clinical Trials Using Axitinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Axitinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • Axitinib and Nivolumab in Treating Patients with Unresectable or Metastatic TFE / Translocation Renal Cell Carcinoma

    This phase II trial studies how well axitinib and nivolumab works in treating patients with TFE / translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating patients with TFE / translocation renal cell carcinoma compared to standard treatment, including surgery, chemotherapy, or immunotherapy.
    Location: 213 locations

  • Axitinib with or without Anti-OX40 Antibody PF-04518600 in Treating Patients with Metastatic Kidney Cancer

    This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.
    Location: 9 locations

  • Axitinib and Avelumab in Treating Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

    This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and avelumab together may help to control adenoid cystic carcinoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Axitinib in Treating Patients with Metastatic, Recurrent, or Primary Unresectable Pheochromocytoma or Paraganglioma

    This phase II trial studies how well axitinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other parts of the body (metastatic), has come back (recurrent), or cannot be removed by surgery (refractory). Axitinib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Axitinib before Surgery in Treating Participants with Localized Clear Cell Kidney Cancer

    This phase II trial studies how well axitinib works before surgery in treating participants with clear cell kidney cancer that has not spread to other parts of the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: University of California San Diego, San Diego, California

  • Survival Prolongation by Rationale Innovative Genomics

    Patients with advanced / metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available) will receive a tri-therapy associating avelumab, axitinib and palbociclib.
    Location: University of California San Diego, San Diego, California

  • Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment. It may also help determine which drugs fight urothelial cancer based on the characteristics of a tumor. Researchers want to test if this model can choose the best therapy for advanced urothelial cancer within 3 weeks and how tumors respond to the next best therapy. Objective: To test if the COXEN model can choose the best therapy for advanced urothelial cancer within 3 weeks. Eligibility: People ages 18 and older whose urothelial cancer has spread after at least 1 line of chemotherapy Design: Participants will be screened with medical history, physical exam, blood and urine tests, and tumor scans. Participants will provide a tumor sample from a previous surgery and a new biopsy. A needle will remove a small piece of tumor. Participants will repeat screening tests, plus have an EKG and scan. For the scan, they will get an injection of radioactive drug. They will lie in a machine that takes pictures. Participants will take the drugs assigned by the COXEN model. They will have visits every 2 3 weeks. These will include blood and urine tests. Participants will have tumor scans every 8 9 weeks. Participants may have another biopsy. Participants will take the drugs until they can t tolerate the side effects or their cancer worsens. They may be assigned to a second COXEN therapy. Participants will have a follow-up visit 4 5 weeks after their last drug dose. Participants will be contacted by phone every few months until death. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Axitinib in Treating Patients with Recurrent or Metastatic Head and Neck Cancer That Cannot Be Removed by Surgery

    This phase II trial studies the best dose of axitinib and how well it works in treating patients with head and neck cancer that has come back, spread from where it started to other places in the body, or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Axitinib and L-Selenomethionine in Treating Patients with Previously Treated Advanced Metastatic Clear Cell Renal Cell Carcinoma

    This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or controlled with treatment (advanced metastatic). L-selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving L-selenomethionine together with axitinib may be a better treatment for advanced metastatic clear cell renal cell carcinoma
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa